Отказ от ответственности: Этот сайт агрегирует общедоступные официальные данные FDA, ClinicalTrials.gov, PubMed и SEC EDGAR только для общей справки. Он не является медицинской консультацией, диагнозом, рекомендацией по лечению или инвестиционным советом.

Клиническое исследование

Efficacy and Safety of Photobiomodulation for Postoperative Pain After Cesarean Section

NCT: NCT07863960 · RECRUITING

NCT IDNCT07863960
СтатусRECRUITING
Дата начала2026-10-01
Завершение2027-02-01
SponsorUniversidad Nacional Autonoma de Honduras (OTHER)
First posted
Last updated

Краткое описание

Postoperative pain following cesarean section remains a major clinical challenge that can impair early maternal recovery, delay ambulation, and interfere with newborn care. Photobiomodulation (PBM) is a non-invasive light therapy that uses red and near-infrared light to reduce inflammation, stimulate cellular energy (ATP) production, and promote tissue repair. The purpose of this randomized, double-blind, sham-controlled clinical trial is to evaluate the efficacy and safety of portable photobiomodulation using the MitoQUAD® device as an adjunct to standard multimodal analgesia in postpartum women undergoing cesarean section. Participants (N=210) will be randomized (1:1) to receive either active PBM or a sham device in three 15-minute sessions (at 30 minutes, 24 hours, and 36-48 hours post-cesarean). Pain intensity, rescue analgesic use, wound healing, time to ambulation, maternal satisfaction, and adverse events will be monitored over 48 hours.

Официальный источник

Открыть на ClinicalTrials.gov →

Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.

↑